All Stories

  1. Assessing measurement bias in substance withdrawal symptoms attributable to childhood adversity and genetic liability

    Article • Drug and Alcohol Dependence, September 2026, Elsevier

    Dr Henry Kranzler

  2. GLP-1 Receptor Agonists as Potential Treatments for Alcohol Use Disorder

    Article • American Journal of Psychiatry, September 2026, American Psychiatric Association

    Dr Henry Kranzler

  3. Investigating genetic overlap of multidimensional pain and suicidal behaviors in >2 million individuals

    Article • June 2026, Springer Science + Business Media

    Dr Henry Kranzler

  4. Education shares distinct genetic influences with substance use and disorder

    Article • Psychological Medicine, January 2026, Cambridge University Press

    Dr Henry Kranzler

  5. Phenome-wide analysis of genetically imputed neuroimaging phenotypes reveals associations with psychiatric traits in a multi-ancestry cohort

    Article • December 2025, openRxiv

    Dr Henry Kranzler

  6. Racial and ethnic disparities in buprenorphine retention and treatment outcome in a longitudinal cohort of U.S. veterans with opioid use disorder

    Article • The American Journal of Drug and Alcohol Abuse, October 2025, Taylor & Francis

    Dr Henry Kranzler

  7. Whole-exome sequencing study of opioid dependence offers novel insights into the contributions of exome variants

    Article • Translational Psychiatry, October 2025, Springer Science + Business Media

    Dr Henry Kranzler

  8. The genetics of cannabis lifetime use

    Article • Neuropsychopharmacology, October 2025, Springer Science + Business Media

    Dr Henry Kranzler

  9. Multi-ancestry Genome-wide Association Study of Inpatient Opioid Dosing Following Knee or Hip Arthroplasty

    Article • August 2025, Springer Science + Business Media

    Dr Henry Kranzler

  10. Polygenic risk and childhood adversity as moderators of drug and alcohol withdrawal symptoms

    Article • Drug and Alcohol Dependence, August 2025, Elsevier

    Dr Henry Kranzler

  11. Multi-ancestry Genome-wide Association Study of Inpatient Opioid Dosing Following Knee or Hip Arthroplasty

    Article • July 2025, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  12. Disaggregating the Genetic Overlap Between Educational Attainment and Substance Use Phenotypes

    Article • July 2025, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  13. Moderation of treatment outcomes by polygenic risk for alcohol‐related traits in placebo‐controlled trials of topiramate

    Article • Alcohol Clinical and Experimental Research, May 2025, Wiley

    Dr Henry Kranzler

  14. Multi‐ancestry genome‐wide association study of topiramate's effects on heavy alcohol use

    Article • Alcohol Clinical and Experimental Research, May 2025, Wiley

    Dr Henry Kranzler

  15. A single-cell genomic atlas for the effects of chronic ethanol exposure in the mouse dorsal striatum

    Article • Molecular Psychiatry, April 2025, Springer Science + Business Media

    Dr Henry Kranzler

  16. Gene discovery and pleiotropic architecture of chronic pain in a genome-wide association study of >1.2 million individuals

    Article • April 2025, Springer Science + Business Media

    Dr Henry Kranzler

  17. Social network alcohol use is associated with individual‐level alcohol use among Black sexually minoritized men and gender‐expansive people: Findings from the Neighborhoods and Networks (N2) cohort study

    Article • Alcohol Clinical and Experimental Research, March 2025, Wiley

    Dr Henry Kranzler

  18. Communication-efficient federated learning of temporal effects on opioid use disorder with data from distributed research networks

    Article • Journal of the American Medical Informatics Association, January 2025, Oxford University Press (OUP)

    Dr Henry Kranzler

  19. Associations of Childhood Adversity and Polygenic Scores with Substance Use Initiation and Disorder Severity

    Article • Psychological Medicine, January 2025, Cambridge University Press

    Dr Henry Kranzler

  20. Associations of Childhood Adversity and Polygenic Scores with Substance Use Initiation and Disorder Severity – ERRATUM

    Article • Psychological Medicine, January 2025, Cambridge University Press

    Dr Henry Kranzler

  21. Integrating HiTOP and RDoC frameworks Part I: Genetic architecture of externalizing and internalizing psychopathology

    Article • Psychological Medicine, January 2025, Cambridge University Press

    Dr Henry Kranzler

  22. Integrating HiTOP and RDoC frameworks part II: shared and distinct biological mechanisms of externalizing and internalizing psychopathology

    Article • Psychological Medicine, January 2025, Cambridge University Press

    Dr Henry Kranzler

  23. A Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi‐ancestry population from the Million Veteran Program

    Article • Alcohol Clinical and Experimental Research, November 2024, Wiley

    Dr Henry Kranzler

  24. Addressing Disparities in Alcohol Use Disorder Treatment: A Call to Action

    Article • American Journal of Psychiatry, November 2024, American Psychiatric Association

    Dr Henry Kranzler

  25. Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders

    Article • Journal of Clinical Investigation, October 2024, American Society for Clinical Investigation

    Dr Henry Kranzler

  26. Association patterns of antisocial personality disorder across substance use disorders

    Article • Translational Psychiatry, August 2024, Springer Science + Business Media

    Dr Henry Kranzler

  27. A genome-wide investigation into the underlying genetic architecture of personality traits and overlap with psychopathology

    Article • Nature Human Behaviour, August 2024, Springer Science + Business Media

    Dr Henry Kranzler

  28. Application of polygenic scores to a deeply phenotyped sample enriched for substance use disorders reveals extensive pleiotropy with psychiatric and somatic traits

    Article • Neuropsychopharmacology, July 2024, Springer Science + Business Media

    Dr Henry Kranzler

  29. Identifying neurofunctional domains across substance use disorders

    Article • The American Journal of Drug and Alcohol Abuse, July 2024, Taylor & Francis

    Dr Henry Kranzler

  30. Gene × environment effects and mediation involving adverse childhood events, mood and anxiety disorders, and substance dependence

    Article • Nature Human Behaviour, June 2024, Springer Science + Business Media

    Dr Henry Kranzler

  31. Combining Transdiagnostic and Disorder-Level GWAS Enhances Precision of Psychiatric Genetic Risk Profiles in a Multi-Ancestry Sample

    Article • May 2024, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  32. Welcoming ACER's new Editor

    Article • Alcohol Clinical and Experimental Research, May 2024, Wiley

    Dr Henry Kranzler

  33. Integrating HiTOP and RDoC Frameworks Part I: Genetic Architecture of Externalizing and Internalizing Psychopathology

    Article • April 2024, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  34. A Multivariate Genome-Wide Association Study Reveals Neural Correlates and Common Biological Mechanisms of Psychopathology Spectra

    Article • April 2024, Springer Science + Business Media

    Dr Henry Kranzler

  35. Genetic and non-genetic predictors of risk for opioid dependence

    Article • Psychological Medicine, February 2024, Cambridge University Press

    Dr Henry Kranzler

  36. Reductions in WHO risk drinking levels correlate with alcohol craving among individuals with alcohol use disorder

    Article • Alcohol Clinical and Experimental Research, January 2024, Wiley

    Dr Henry Kranzler, Dr. Katie Witkiewitz

  37. Prevalence and correlates of DSM-5 opioid withdrawal syndrome in U.S. adults with non-medical use of prescription opioids: results from a national sample

    Article • The American Journal of Drug and Alcohol Abuse, November 2023, Taylor & Francis

    Dr Henry Kranzler

  38. Comparing the Psychometric Properties of Reward and Relief Drinking Measures

    Article • October 2023, Center for Open Science

    Dr Henry Kranzler, Dr. Katie Witkiewitz

  39. Adverse Childhood Events, Mood and Anxiety Disorders, and Substance Dependence: Gene x Environment Effects and Moderated Mediation

    Article • October 2023, Springer Science + Business Media

    Dr Henry Kranzler

  40. Adverse Childhood Events, Mood and Anxiety Disorders, and Substance Dependence: Gene X Environment Effects and Moderated Mediation

    Article • October 2023, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  41. Demographic differences in the cascade of care for unhealthy alcohol use: A cross‐sectional analysis of data from the 2015–2019 National Survey on Drug Use and Health

    Article • Alcohol Clinical and Experimental Research, September 2023, Wiley

    Dr Henry Kranzler

  42. Medications for treating alcohol use disorder: A narrative review

    Article • Alcohol Clinical and Experimental Research, June 2023, Wiley

    Dr Henry Kranzler

  43. Genetic Underpinnings of the Transition From Alcohol Consumption to Alcohol Use Disorder: Shared and Unique Genetic Architectures in a Cross-Ancestry Sample

    Article • American Journal of Psychiatry, June 2023, American Psychiatric Association

    Dr Henry Kranzler

  44. Identifying genetic loci and phenomic associations of substance use traits: A multi‐trait analysis of GWAS (MTAG) study

    Article • Addiction, May 2023, Wiley

    Dr Henry Kranzler

  45. Metabolic Profiles Associated with Opioid Use and Opioid Use Disorder: a Narrative Review of the Literature

    Article • Current Addiction Reports, May 2023, Springer Science + Business Media

    Dr Henry Kranzler

  46. Does polygenic risk for substance‐related traits predict ages of onset and progression of symptoms?

    Article • Addiction, May 2023, Wiley

    Dr Henry Kranzler

  47. Multi-trait genome-wide association analyses leveraging alcohol use disorder findings identify novel loci for smoking behaviors in the Million Veteran Program

    Article • Translational Psychiatry, May 2023, Springer Science + Business Media

    Dr Henry Kranzler

  48. Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans

    Article • American Journal of Psychiatry, May 2023, American Psychiatric Association

    Dr Henry Kranzler

  49. The genetic architecture of pain intensity in a sample of 598,339 U.S. veterans

    Article • March 2023, Springer Science + Business Media

    Dr Henry Kranzler

  50. Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans

    Article • Alcohol Clinical and Experimental Research, February 2023, Wiley

    Dr Henry Kranzler

  51. An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial

    Article • Addiction, January 2023, Wiley

    Dr Henry Kranzler, Dr. Katie Witkiewitz

  52. Announcing a name change for ACER

    Article • Alcohol Clinical and Experimental Research, December 2022, Wiley

    Dr Henry Kranzler

  53. Polygenic Risk for Substance-Related Traits Predicts Substance Use Onset and Progression: Sex and Population Group Differences

    Article • September 2022, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  54. A randomized, double‐blind, placebo‐controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder

    Article • Alcoholism Clinical and Experimental Research, September 2022, Wiley

    Dr Henry Kranzler

  55. Integrating human brain proteomic data with genome-wide association study findings identifies novel brain proteins in substance use traits

    Article • Neuropsychopharmacology, August 2022, Springer Science + Business Media

    Dr Henry Kranzler

  56. Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data

    Article • Addiction, July 2022, Wiley

    Dr Henry Kranzler

  57. Using 18F-NOS PET Imaging to Measure Pulmonary Inflammation in Electronic and Combustible Cigarette Users: A Pilot Study

    Article • June 2022, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  58. Association of Topiramate Prescribed for any Indication with Reduced Alcohol Consumption in Electronic Health Record Data

    Article • May 2022, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  59. Is it time to rethink low‐risk drinking guidelines?

    Article • Alcoholism Clinical and Experimental Research, April 2022, Wiley

    Dr Henry Kranzler

  60. Associations between alcohol consumption and gray and white matter volumes in the UK Biobank

    Article • Nature Communications, March 2022, Springer Science + Business Media

    Dr Henry Kranzler

  61. Alcohol withdrawal in past‐year drinkers with unhealthy alcohol use: Prevalence, characteristics, and correlates in a national epidemiologic survey

    Article • Alcoholism Clinical and Experimental Research, March 2022, Wiley

    Dr Henry Kranzler

  62. Using phenotype risk scores to enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder

    Article • Molecular Psychiatry, February 2022, Springer Science + Business Media

    Dr Henry Kranzler

  63. Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation

    Article • Alcoholism Clinical and Experimental Research, February 2022, Wiley

    Dr Henry Kranzler

  64. Genome-wide meta-analysis of alcohol use disorder in East Asians

    Article • Neuropsychopharmacology, January 2022, Springer Science + Business Media

    Dr Henry Kranzler

  65. Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials

    Article • Addiction Biology, January 2022, Wiley

    Dr Henry Kranzler

  66. Identifying and Reducing Bias in Genome-Wide Association Studies of Alcohol-Related Traits

    Article • American Journal of Psychiatry, January 2022, American Psychiatric Association

    Dr Henry Kranzler

  67. Placebo-controlled trial of bupropion for smoking cessation in pregnant women

    Article • American Journal of Obstetrics & Gynecology MFM, November 2021, Elsevier

    Dr Henry Kranzler

  68. Genetic liability for substance use associated with medical comorbidities in electronic health records of African‐ and European‐ancestry individuals

    Article • Addiction Biology, October 2021, Wiley

    Dr Henry Kranzler

  69. Analysis of genetic and clinical factors associated with buprenorphine response

    Article • Drug and Alcohol Dependence, October 2021, Elsevier

    Dr Henry Kranzler

  70. Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder

    Article • Drug and Alcohol Dependence, August 2021, Elsevier

    Dr Henry Kranzler, Dr. Katie Witkiewitz

  71. Comorbid-phenome prediction and phenotype risk scores enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder

    Article • July 2021, Cold Spring Harbor Laboratory Press

    Dr Henry Kranzler

  72. World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials

    Article • Alcoholism Clinical and Experimental Research, July 2021, Wiley

    Dr Henry Kranzler, Dr. Katie Witkiewitz

  73. Genome-wide association study of stimulant dependence

    Article • Translational Psychiatry, June 2021, Springer Science + Business Media

    Dr Henry Kranzler

  74. The impact of removing former drinkers from genome‐wide association studies of AUDIT‐C

    Article • Addiction, May 2021, Wiley

    Dr Henry Kranzler

  75. Accuracy of Consumer‐marketed smartphone‐paired alcohol breath testing devices: A laboratory validation study

    Article • Alcoholism Clinical and Experimental Research, May 2021, Wiley

    Dr Henry Kranzler

  76. Correction to: Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder

    Article • Neuropsychopharmacology, April 2021, Springer Science + Business Media

    Dr Henry Kranzler

  77. The phenomics and genetics of addictive and affective comorbidity in opioid use disorder

    Article • Drug and Alcohol Dependence, April 2021, Elsevier

    Dr Henry Kranzler

  78. Reward drinking and naltrexone treatment response among young adult heavy drinkers

    Article • Addiction, March 2021, Wiley

    Dr Henry Kranzler, Dr. Katie Witkiewitz

  79. Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder

    Article • Neuropsychopharmacology, February 2021, Springer Science + Business Media

    Dr Henry Kranzler

  80. Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial

    Article • Neuropsychopharmacology, February 2021, Springer Science + Business Media

    Dr Henry Kranzler

  81. Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms

    Article • Circulation Genomic and Precision Medicine, February 2021, Wolters Kluwer Health

    Dr Henry Kranzler

  82. Genetic underpinnings of risky behaviour relate to altered neuroanatomy

    Article • Nature Human Behaviour, January 2021, Springer Science + Business Media

    Dr Henry Kranzler

  83. Multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidality

    Article • Translational Psychiatry, January 2021, Springer Science + Business Media

    Dr Henry Kranzler

  84. A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder

    Article • The International Journal of Neuropsychopharmacology, September 2020, Oxford University Press (OUP)

    Dr Henry Kranzler

  85. Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study

    Article • Nicotine & Tobacco Research, April 2020, Oxford University Press (OUP)

    Dr Henry Kranzler

  86. World Health Organization Risk Drinking Level Reductions Are Associated with Improved Functioning and Are Sustained Among Patients with Mild, Moderate, and Severe Alcohol Dependence in Clinical Trials in the United States and United Kingdom

    Article • Addiction, February 2020, Wiley

    Dr Henry Kranzler, Dr. Katie Witkiewitz

  87. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence

    Article • The Pharmacogenomics Journal, February 2020, Springer Science + Business Media

    Dr Henry Kranzler

  88. Genome-Wide Association Study of Opioid Cessation

    Article • Journal of Clinical Medicine, January 2020, MDPI AG

    Dr Henry Kranzler

  89. Author Correction: Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women

    Article • Scientific Reports, December 2019, Springer Science + Business Media

    Dr Henry Kranzler

  90. Genomewide Gene-by-Sex Interaction Scans Identify ADGRV1 for Sex Differences in Opioid Dependent African Americans

    Article • Scientific Reports, December 2019, Springer Science + Business Media

    Dr Henry Kranzler

  91. A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans

    Article • Translational Psychiatry, November 2019, Springer Science + Business Media

    Dr Henry Kranzler

  92. Author Correction: Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations

    Article • Nature Communications, September 2019, Springer Science + Business Media

    Dr Henry Kranzler

  93. A meta‐analysis of the efficacy of gabapentin for treating alcohol use disorder

    Article • Addiction, June 2019, Wiley

    Dr Henry Kranzler

  94. Author Correction: Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations

    Article • Nature Communications, May 2019, Springer Science + Business Media

    Dr Henry Kranzler

  95. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations

    Article • Nature Communications, April 2019, Springer Science + Business Media

    Dr Henry Kranzler

  96. Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population

    Article • Drug and Alcohol Dependence, April 2019, Elsevier

    Dr Henry Kranzler

  97. Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women

    Article • Scientific Reports, March 2019, Springer Science + Business Media

    Dr Henry Kranzler

  98. Alcohol-responsive genes identified in human iPSC-derived neural cultures

    Article • Translational Psychiatry, March 2019, Springer Science + Business Media

    Dr Henry Kranzler

  99. GWAS and network analysis of co-occurring nicotine and alcohol dependence identifies significantly associated alleles and network

    Article • American Journal of Medical Genetics Part B Neuropsychiatric Genetics, November 2018, Wiley

    Dr Henry Kranzler

  100. Genome-wide association study identifies glutamate ionotropic receptor GRIA4 as a risk gene for comorbid nicotine dependence and major depression

    Article • Translational Psychiatry, October 2018, Springer Science + Business Media

    Dr Henry Kranzler